LEBANON, N.J. and BETHESDA, Md., Feb. 23, 2015 /PRNewswire/ — Celimmune LLC, a clinical development-stage immunotherapy company targeting autoimmunity and inflammation, today announced that it will initially focus its distinctive core competence in translational medicine, immunotherapy clinical development and commercialization on combating celiac disease. Read more HERE
